PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Lucia M. Novak, MSN, ANP-BC, BC-ADM - Individualizing Management Plans for Type 2 Diabetes Through Shared Decision-Making: An Office Hours Activity Feb 10, 2025

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/UTJ865. CME/NCPD/AAPA credit will be available until February 28, 2026.

Individualizing Management Plans for Type 2 Diabetes Through Shared Decision-Making: An Office Hours Activity

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Professor Melanie Davies - Understanding the Individual in Front of You: The Importance of Patient Participation in Weight and Glycaemic Management for People With Type 2 Diabetes Jan 31, 2025

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EYG865. CME credit will be available until January 23, 2026.

Understanding the Individual in Front of You: The Importance of Patient Participation in Weight and Glycaemic Management for People With Type 2 Diabetes

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Vanita R. Aroda, MD - Intensifying Treatment for Type 2 Diabetes According to Current Guidelines: An Office Hours Activity Jan 03, 2025

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NRC865. CME/NCPD/AAPA credit will be available until January 11, 2025.

Intensifying Treatment for Type 2 Diabetes According to Current Guidelines: An Office Hours Activity

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Javed Butler, MD, MPH, MBA / Muthiah Vaduganathan, MD, MPH - Experts vs AI: Exploring New Paradigms in Comprehensive Care for Cardio-Renal-Metabolic Diseases Dec 09, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RWH865. CME credit will be available until December 16, 2025.

Experts vs AI: Exploring New Paradigms in Comprehensive Care for Cardio-Renal-Metabolic Diseases

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Disclosure information is available at the beginning of the video presentation.

Guillermo E. Umpierrez, MD, CDE, FACP, FACE - Prioritizing Weight Management as a Primary Goal in People With Type 2 Diabetes: An Office Hours Activity Nov 11, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/RWC865. CME/NCPD/AAPA credit will be available until November 29, 2025.

Prioritizing Weight Management as a Primary Goal in People With Type 2 Diabetes: An Office Hours Activity

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Irl Hirsch, MD, MACP - The New Normal: Digital Technologies for People Living With Insulin-Treated Type 2 Diabetes Nov 11, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/UHT865. CME/NCPD/AAPA credit will be available until October 31, 2025.

The New Normal: Digital Technologies for People Living With Insulin-Treated Type 2 Diabetes

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure information is available at the beginning of the video presentation.

John E. Anderson, MD - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal Aug 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/USQ865. CME/NCPD/AAPA credit will be available until August 15, 2025.

Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

P. Barton Duell, MD - Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies Aug 20, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/QMF865. CME credit will be available until August 15, 2025.

Lipid Management Beyond Statins: Early Screening, Prompt Intervention, and Timely Intensification With PCSK9-Targeted Therapies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

Javier Morales, MD, FACP, FACE - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People with T2DM Jun 19, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/ZKT865. CME/CE/AAPA credit will be available until June 11, 2025.

Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People with T2DM

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Javier Morales, MD, FACP, FACE - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal Mar 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WMV865. CME/NCPD/AAPA credit will be available until March 25, 2025.

Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

R. Scott Wright, MD - Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management Feb 28, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/GVK865. CME credit will be available until February 13, 2025.

Targeting Elevated Cardiovascular Risk: Current Therapies and New Horizons in Hyperlipidemia Management

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosures
R. Scott Wright, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Novo Nordisk Inc.

CME Reviewer

Ramil Goel
Assistant Professor of Medicine
Division of Cardiovascular Medicine
Electrophysiology Section
University of Florida College of Medicine
Gainesville, Florida

Ramil Goel, MD, FHRS, has no relevant financial relationships to disclose.

Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS - Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey Jan 31, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/ANR865. CME/MOC/CC/NCPD/CPE/AAPA/IPCE credit will be available until January 16, 2025.

Adapting Our Strategies for Decision-Making in Testing and Treatment of RET-Altered Lung and Thyroid Cancers: A Personalized Learning Journey

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Professor Benjamin Solomon, MBBS, PhD, FRACP, FAHMS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Bristol Myers Squibb; D3 BIO, INC; F. Hoffmann-La Roche AG; Janssen Pharmaceuticals, Inc.; Lilly; Merck Sharpe & Dohme; Pfizer; and Takeda Pharmaceutical Company.
Speakers Bureau participant with AstraZeneca; F. Hoffmann-La Roche AG; and Pfizer.

Co-Chair/Planner
Lori J. Wirth, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Blueprint Medicines Corporation; Coherus BioSciences; Eisai Co., Ltd.; Ellipses Pharma Ltd; EMD Serono, Inc.; Exelixis, Inc.; Lilly; Merck & Co., Inc.; and Nested Therapeutics.
Data Safety Monitoring Board for PDS Biotechnology.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Stefano Del Prato, MD - Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making Jan 04, 2024

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CPD information, and to apply for credit, please visit us at PeerView.com/BVW865. CME/CPD credit will be available until December 27, 2024.

Tools of the Trade: Prioritising Weight Management in People With Type 2 Diabetes – Sharpening Your Skills to Intensify Therapy and Engage in Shared Decision-Making

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Stefano Del Prato, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; Amarin Corporation plc; Applied Therapeutics; EvaPharma; Lilly; The Menarini Group; Novo Nordisk A/S; Sanofi; and Sun Pharmaceutical Industries Ltd.
Speaker for Abbott; AstraZeneca; Berlin-Chemie AG; Boehringer Ingelheim International GmbH; Laboratori Guidotti S.p.a.; Lilly; The Menarini Group; Merck Sharp & Dohme; and Novo Nordisk A/S.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Javier Morales, MD, FACP, FACE / Jay H. Shubrook, DO, FAAFP, FACOFP - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM Dec 01, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/XCX865. CME/AAPA credit will be available until November 26, 2024.
Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Javier Morales, MD, FACP, FACE, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.
Speaker for Amgen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.
Co-Chair/Planner
Jay H. Shubrook, DO, FAAFP, FACOFP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Lilly; Nevro Corp.; and Novo Nordisk Inc.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Hiddo J.L. Heerspink, PhD, PharmD / Prof. Dr. med Christoph Wanner - Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care Nov 07, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZSZ865. CME credit will be available until November 4, 2024.
Chronic Kidney Disease in Patients With Type 2 Diabetes: The Impetus for Early Recognition and Strategies for Coordinating Optimal, Patient-Centered Care
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Hiddo J.L. Heerspink, PhD, PharmD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Chinook Therapeutics Inc.; CSL Behring; Dimerix; Gilead Sciences, Inc.; Janssen-Cilag B.V.; Lilly; Merck & Co., Inc.; Novartis AG; Novo Nordisk A/S; and Travere Therapeutics, Inc.
Grant/Research Support from AstraZeneca; Janssen-Cilag B.V.; and Novo Nordisk A/S.
Speaker for AstraZeneca; Lilly; and Novo Nordisk A/S.
Co-Chair/Planner
Prof. Dr. med Christoph Wanner has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; GSK; and Merck Sharp & Dohme.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.
Speaker for AstraZeneca; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; and GSK.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Jaime Almandoz, MD, MBA, FTOS - Leading the Charge to Change the Obesity Narrative: Supporting Primary Care to Improve Weight Management Discussions, Diagnosis, and Decisions Sep 20, 2023

Go online to PeerView.com/XZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the United States, the prevalence of obesity has been steadily increasing. Despite the number of obesity specialists in the United States multiplying five-fold from 2011 to 2019, there is an inadequate number of trained professionals to treat all people requiring obesity-targeted care. Primary care is often the first and only touch point for many people with obesity (PwO), and there is a need to equip and prepare primary care professionals (PCPs) to treat this patient population with empathetic, effective, and evidence-based obesity-targeted care. This PeerView Train-the-Trainer MasterClass activity combines concise overviews of essential evidence with training resources to help you, as an obesity specialist, lead the charge to educate your PCP colleagues. Using practical exercises, experts provide guidance on strategies and tactics you can use to create your own training workshop for PCPs. In addition to the Train-the-Trainer video, participants also have free access to a slide library, surveys, and practice aids to create their own independent training workshop. Upon completion of this activity, participants should be better able to: Address misperceptions and weight biases held by many PCPs to minimize the downstream effects and complications in people with obesity; and Assist PCPs in combating clinical inertia and encouraging early intervention in people with or at risk for obesity

Richard Keen, PhD, FRCP, Edna E. Mancilla, MD - Can YOU Avoid Iatrogenic Harm? Understanding and Identifying Fibrodysplasia Ossificans Progressiva Sep 20, 2023

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NYY865. CME credit will be available until August 30, 2024.
Can YOU Avoid Iatrogenic Harm? Understanding and Identifying Fibrodysplasia Ossificans Progressiva
In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and International Fibrodysplasia Ossificans Progressiva Association ,Progressive Osseous & Heteroplasia Association ,The American Society for Bone and Mineral Research. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Co-Chair/Planner
Richard Keen, PhD, FRCP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ipsen Biopharmaceuticals, Inc.; Kyowa Kirin Co., Ltd; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Grant/Research Support from Incyte; Ipsen Biopharmaceuticals, Inc.; Kyowa Kirin Co., Ltd; and Regeneron Pharmaceuticals Inc.
Speaker for Ipsen Biopharmaceuticals, Inc.; Kyowa Kirin Co., Ltd; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Co-Chair/Planner
Edna E. Mancilla, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ipsen Biopharmaceuticals, Inc./Clementia Pharmaceuticals.
Grant/Research Support from Incyte.
Patient/Planner
Erin Danzer has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Kara Mayes, MD, FAAFP / Jay H. Shubrook, DO, FAAFP, FACOFP - Now Is the Time to Overcome Therapeutic Inertia in T2D to Achieve Personalized Glycemic and Weight Management Goals Aug 31, 2023

Go online to PeerView.com/PQU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes (T2D) is a progressive disease that is largely preventable and entirely treatable. Timely intensification of therapy is a foundational principle of contemporary management of people with T2D since this strategy is associated with better long-term health outcomes. In conjunction with intensified therapy, modest weight loss has been shown to improve overall and long-term health outcomes. In this activity, based on a series of Project ECHO® workshops and produced in collaboration with the American College of Diabetology, you’ll learn best practices for individualizing patient care and intensifying therapy with evidence-based pharmacologic management of T2D with non-insulin glucose-lowering therapies. Now is the time! Watch today to begin adding these practical strategies to your toolbox! Upon completion of this activity, participants should be better able to: Intensify treatment in people with T2D consistent with the latest guidelines, available evidence, and shared decision-making principles to control glycemia and weight to optimize outcomes and avoid long-term complications; Explain the rationale for targeting weight and establish personalized weight loss goals as a treatment priority for comprehensive T2D management; and Counsel people with T2D about the relationship between obesity and diabetes and the importance of achieving and maintaining a healthy weight as a T2D treatment priority.

Bradley S. Miller, MD, PhD - Improving Outcomes in Pediatric Growth Hormone Deficiency With Effective Diagnosis and Personalized Management Strategies Aug 11, 2023

Go online to PeerView.com/ZAB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of recombinant human growth hormone (rhGH) therapy has facilitated wider treatment of growth hormone deficiency. In this CME-certified MasterClass & Practicum video activity, expert faculty will review current guidelines for pediatric growth hormone deficiency diagnosis, growth hormone therapy indications, and characteristics of available and emerging growth hormone therapies. Tune in today to increase your knowledge and competence on the diagnosis and management of growth hormone deficiency with rhGH therapy, including long-acting growth hormone agents, and gain a better understanding of how to address patient needs. Upon completion of this activity, participants should be better able to: Utilize relevant diagnostic tests to provide timely diagnosis of pediatric patients suspected to have growth hormone deficiency; Compare the clinical characteristics and supporting evidence (eg, efficacy, safety and tolerability, ease of administration, dosing frequency) for various options in growth hormone therapy; and Incorporate growth hormone therapy into personalized management plans to address pediatric patient challenges such as dosage concerns, administration, adherence, and monitoring.

Vanita R. Aroda, MD - Leveraging Early GLP-1 RA Initiation to Reduce Risks and Improve Long-Term Outcomes in Patients With T2DM Jul 28, 2023

Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM

Athena Philis-Tsimikas, MD - Episode 4: Exploring Therapeutic Potential of Once-Weekly Basal Insulin Therapy Jul 24, 2023

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Athena Philis-Tsimikas, MD - Episode 3: Practical Considerations for Once-Weekly Basal Insulin Therapy Jul 24, 2023

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Athena Philis-Tsimikas, MD - Episode 2: Overcoming Clinical Inertia in Patients With T2DM Jul 24, 2023

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

Athena Philis-Tsimikas, MD - Episode 1: Current Guidance and Indications for Basal Insulin in Patients With T2DM Jul 24, 2023

Go online to PeerView.com/KNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is indispensable to the treatment of diabetes, but its use in people with diabetes presents numerous well-known challenges. As many as 40% of people with T2DM require insulin therapy, but only about one-third initiate basal insulin. How can endocrinologists and other healthcare providers ease the treatment burden for these patients? Part of the answer may lie in once-weekly basal insulins. This PeerView inQuiry challenges you to examine the role of once-weekly basal insulins and how they may help to improve outcomes in patients with diabetes. Four assessment questions will keep you on your toes, and an expert will share short, authoritative explanations on the latest clinical data, rationale for use, dosing and tips and strategies for helping patients achieve glycemic targets with less frequent basal insulin injection. Upon completion of this activity, participants should be better able to: Compare the efficacy, safety, administration, and dosing frequency of once-weekly with once-daily basal insulins; and Identify patients with T2DM that are not meeting individualized glycemic goals and who may benefit from basal insulin therapy, including once-weekly formulations, as they become available

John B. Buse, MD, PhD - Scoring Comprehensive T2DM Management Goals: Examining the Multifaceted Effects of GLP-1 Receptor Agonists Jul 06, 2023

Go online to PeerView.com/ZKJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Type 2 diabetes mellitus (T2DM) is a worldwide health concern. With more people living longer, the prevalence of chronic comorbid diseases has increased dramatically, and there is a resurgence in diabetic complications. T2DM shares risk factors with atherosclerotic cardiovascular disease (ASCVD), the leading cause of death among patients with T2DM. Furthermore, T2DM is a leading cause of kidney failure. How can clinicians address the underlying pathophysiology and comorbid organ damage that is frequently associated with T2DM? This activity seeks to answer that question using patient cases to examine where GLP-1 receptor agonists (RAs) fit in modern treatment algorithms and help recognize the differences between GLP-1 RA options. Importantly, you’ll also hear practical strategies to help navigate the ins and outs of patient-centered care. Upon completion of this activity, participants should be better able to: Explain the rationale for using GLP-1 RAs in comprehensive T2DM management plans to optimize patient outcomes and reduce the risk of associated complications; Compare current and emerging agents targeting GLP-1 based on their mechanisms of action, dosing frequency, efficacy, safety, and tolerability profiles; Identify patients who would benefit from the multifaceted glycemic and extra-glycemic effects of GLP-1 RAs as part of comprehensive T2DM management plans; and Counsel, as a member of a multidisciplinary care team, patients with T2DM about the long-term efficacy, safety, and convenience that GLP-1 RAs have to offer as a means to achieving individualized glycemic and non-glycemic health goals

Juan Pablo Frías, MD - Case in Point: Addressing Practical Questions to Improve Long-Term Outcomes in Patients With Obesity Jul 05, 2023

Go online to PeerView.com/KEW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Early intervention is central to reducing excess weight gain and the risk of obesity-related comorbidities, yet many people never receive a formal diagnosis or specialty obesity care. With this in mind, how can clinicians best support this patient population? Endocrinologists, in particular, are on the front lines of managing and treating this complex disease. In this PeerView inReview, an expert uses patient videos to explain what you need to know about effective, compassionate patient communication and offers practical guidance on how to best integrate anti-obesity medications into patient care to improve long-term outcomes. Upon completion of this activity, participants should be better able to: Prioritize obesity as a chronic, progressive disease that requires individualized, long-term management; Initiate nonjudgmental conversations with individuals living with obesity and engage in effective shared decision-making discussions to achieve sustained weight loss; Compare the mechanism of action, efficacy, and safety of approved and emerging medications for the long-term management of obesity; and Identify people with obesity who could benefit from treatment with anti-obesity medications

Jaime Almandoz, MD, MBA, FTOS - Practicing What We Preach: Your Role as an Obesity Medicine Specialist, Inspiring Change, and Overcoming Negative Weight Biases to Prioritize the Management of Obesity as a Chronic Disease Jun 20, 2023

Go online to PeerView.com/QFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging activity, which is based on a pre-conference workshop held at OMA 2023, experts in obesity management aim to change misperceptions about obesity and explain best practices for treating this chronic condition, which include the importance of anti-obesity medications (AOMs) in achieving individualized weight goals and improving overall health outcomes by reducing the risk and progression of obesity-related comorbidities. Upon completion of this activity, participants should be better able to: Initiate appropriate, unbiased, and nonjudgmental conversations with patients about obesity acknowledging it as a chronic, treatable disease rather than a result of personal irresponsibility; Compare the efficacy and safety profiles of current and emerging anti-obesity medications and their potential to support weight loss efforts and minimize the impact of obesity-related comorbidities; and Employ shared decision-making to implement a comprehensive, individualized treatment plan that incorporates appropriate use of long-term anti-obesity medications to achieve and maintain realistic weight loss in people with obesity.

Richard K. Bogan, MD, FCCP, FAASM - Managing Disorders of Hypersomnolence: Reducing Patient Burdens, Protecting Patient Health Nov 14, 2022

Go online to PeerView.com/JKX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert in hypersomnolence discusses the diagnosis, classification, and treatment of narcolepsy and idiopathic hypersomnia. Using real-life cases as examples, the latest data and guidelines are reviewed in juxtaposition with the patients’ stories. Upon completion of this activity, participants should be better able to: Describe how delayed diagnosis of narcolepsy or idiopathic hypersomnia (IH) exacerbates the multifaceted burdens associated with both conditions; Apply International Classification of Sleep Disorders criteria to assess patients who present with excessive daytime sleepiness (EDS) or other signs or symptoms suggesting narcolepsy or IH; and Individualize treatment of narcolepsy and IH, based on the latest clinical evidence and guidelines; patient needs, preferences, and comorbidities; and considerations that affect adherence.

Mark W. Stolar, MD - A Call to Action for Primary Care Professionals: Your Role in Saving the Eyesight of Patients With Diabetes Nov 02, 2022

Go online to PeerView.com/FZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Timely screenings and referrals to eye care specialists for diabetic retinopathy (DR) and diabetic macular edema (DME) can make a real difference between good vision and blindness in patients with diabetes. But exactly when should patients with diabetes be screened for DR/DME in the primary care setting and which signs and symptoms should trigger a referral to specialty care? In this activity, based on a recent live virtual symposium, leading experts review guideline recommendations for DR/DME screening and referral in the primary care setting and present realistic patient cases to explore best practices and improve vision outcomes for patients with diabetes. Upon completion of this activity, participants should be better able to: Describe the roles of primary care professionals in the screening and referral process for DR/DME and other diabetic eye diseases; Coordinate timely and appropriate referral to eye care specialists who can utilize effective treatment regimens for DR/DME and other diabetic eye diseases; and Incorporate interprofessional and multidisciplinary strategies to overcome barriers to referral using an integrated system of care approach for screening, diagnosis, and treatment of vision-threatening diabetic eye complications such as DR/DME.

Jay H. Shubrook, DO, FAAFP, FACOFP - Tools of the Trade: A Practical Guide to Managing NASH Oct 20, 2022

Go online to PeerView.com/ACR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses how to utilize the American Gastroenterological Association’s Clinical Care Pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Upon completion of this activity, participants should be better able to: List the disease pathways and mechanisms that define NASH as a metabolic disease; Identify the pathophysiology and role of GLP-1 as a therapeutic target in NASH; Differentially diagnose NASH in a timely manner; Integrate current and emerging agents into early management plans for patients with NASH based on the AGA NASH Clinical Care Pathway

Marcia S. Brose, MD, PhD, FASCO - Optimizing NTRK Fusion Testing and TRK Inhibition in Thyroid Cancer: Team-Based Approaches for Enhanced Outcomes Oct 04, 2022

Go online to PeerView.com/QKA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this inExchange from PeerView, a multidisciplinary team of experts from oncology, endocrinology, and pathology discuss the advantages of a team-based approach to NTRK fusion testing and TRK inhibition in thyroid cancer. In this 30-minute learning opportunity, you’ll hear how endocrinologists can lead the interprofessional charge to enhance outcomes by optimizing NTRK fusion testing and TRK-targeted therapy. This presentation covers the rationale, science, and evidence, and presents actionable strategies for putting the data into practice for patients with fusion-positive thyroid cancer. Upon completion of this activity, participants should be better able to: Explain the rationale for testing for NTRK fusions in patients with thyroid cancer, including their role in disease development and progression and impact on prognosis and treatment algorithms; Cite current efficacy and safety evidence on TRK-targeted therapies in patients with NTRK fusion–positive thyroid cancers; Implement practical strategies to ensure patients with thyroid cancer receive timely and appropriate NTRK fusion testing in order to inform optimal therapeutic decision-making; and Apply best practices for collaboration and coordination of care with multidisciplinary colleagues for patients with NTRK fusion–positive thyroid cancer, including appropriate integration of TRK-targeted therapies into treatment plans and recognition/management of treatment-related adverse events.

Domenica M. Rubino, MD - Getting Ahead of the Curve: Identifying and Managing Obesity in Primary Care Aug 11, 2022

Go online to PeerView.com/DBP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on obesity management discusses current evidence for anti-obesity medications and shares evidence-based strategies to individualize weight-loss regimens and improve health outcomes. Upon completion of this activity, participants should be better able to: Recognize the role of weight-loss pharmacotherapy for reducing risks and addressing obesity as a chronic disease, including effects on appetite regulation, metabolic adaptation, and preventing/managing obesity-related complications, adjunct to lifestyle modification; Assess current guidance and available long-term efficacy and safety data for current and emerging weight-loss pharmacotherapies in people with or at risk for obesity; and Incorporate weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.

Richard Beaser, MD - A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes Aug 10, 2022

Go online to PeerView.com/TFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Who holds the key that can unlock the door to vision-saving treatments for patients with diabetic retinopathy (DR) and diabetic macular edema (DME)? The answer is primary diabetes care professionals: Timely screening and referral to eye care professionals can make a real difference between good vision and blindness for patients with DR/DME. The diagnosis and treatment of DR/DME has advanced greatly in the last decade. What can endocrinologists, diabetologists, and primary diabetes care professionals tell their patients to expect when they meet with a retina specialist? In this activity, based on a recent PeerView Live event, leading experts take a well-rounded look at the screening, diagnosis, and referral for treatment of individuals with DR/DME, including a practical review of the evidence for current and emerging treatment options. The experts discuss patient cases with varying degrees of urgency for referral, offering a glimpse into how decisions made by primary diabetes care professionals can speed access to the appropriate eye care professional to directly benefit and improve outcomes for patients with, or at risk for, DR/DME. Upon completion of this activity, participants should be better able to: Describe the roles of diabetes specialists in the screening and referral process for DR/DME and other diabetic eye diseases; Coordinate timely and appropriate referrals to eye care specialists who can utilize effective treatment regimens for DR/DME and other diabetic eye diseases; and Incorporate interprofessional and multidisciplinary strategies to overcome barriers to referral using an integrated system of care approach for screening, diagnosis, and treatment of vision-threatening diabetic eye complications such as DR/DME.

Rajiv Agarwal, MD, MS - A Renewed Look at MRA Therapy: Improving Renal Outcomes and Reducing Risks in Patients With Type 2 Diabetes May 26, 2022

Go online to PeerView.com/JNH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert nephrologist examines the pathophysiology of chronic kidney disease (CKD) and the effects of mineralocorticoid receptor overactivation in patients with type 2 diabetes (T2D) to offer practical strategies for identifying which patients with CKD and T2D may benefit from treatment with nonsteroidal MRAs. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of CKD progression and the effects of mineralocorticoid receptor overactivation in patients with T2D, Compare the mechanism of action, potency, selectivity, and physiological distribution of steroidal and nonsteroidal MRAs, Identify patients with CKD and T2D that may derive specific benefit from treatment with nonsteroidal MRAs.

Lucia M. Novak, MSN, ANP-BC, BC-ADM - Building Skills for Clinical Practice: Optimizing Insulin Management and Personalizing Diabetes Care With Faster-Acting Formulations and Newer Options in Delivery Technology May 19, 2022

Go online to PeerView.com/TZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Insulin is often a necessary treatment for people with diabetes. Yet, knowing when to properly initiate and titrate insulin therapy in people with type 1 and type 2 diabetes is unfamiliar to many clinicians. In this activity, an expert discusses current guidance for incorporating individual preferences in insulin therapy in a variety of treatment regimens, models effective communication strategies in telehealth visits, and offers approaches to overcome common barriers to therapeutic inertia and engage patients to improve time in range and reduce postprandial glucose excursions. Upon completion of this activity, participants should be better able to: Incorporate newer options in mealtime insulin and the latest advances in technology to overcome barriers to insulin initiation, simplify insulin delivery and dosing, improve postprandial glucose (PPG) levels and time in range (TIR), and enhance the quality of life in patients with insulin-treated diabetes, Engage in patient-centered discussions across the interprofessional care team to optimize use of the latest advances in rapid acting insulin and insulin technology to support patient-centered diabetes care.

Javier Morales, MD, FACP, FACE - Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity May 06, 2022

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants should be better able to: Identify the individual role the incretin hormone GIP plays in healthy physiology and the synergistic role it has when combined with GLP-1, Differentiate the mechanism of action of dual GIP/GLP-1 RA therapy from GLP-1 RAs and its resulting effects on glycemic control, body weight, and lipid metabolism in patients with T2DM, Intensify therapy in a timely and patient-centered manner to optimize control of glycemia and weight consistent with the latest available evidence and avoid long-term complications in patients with T2DM and obesity.

J. Fernando Arevalo - Seeing Eye to Eye: Improving Outcomes Among Rural Spanish-Speaking Latinx Patients With Diabetic Retinopathy or Diabetic Macular Edema Apr 06, 2022

Go online to PeerView.com/DRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in ophthalmology discusses improving vision outcomes among Spanish-speaking patients with DR and DME, including those residing in rural areas. Upon completion of this CE activity, participants will be able to: Describe the barriers that Spanish-speaking individuals, especially those living in rural areas, frequently encounter when seeking a diagnosis and/or treatment of DR/DME, Construct coordinated care plans with multidisciplinary providers (eg, PCPs, endocrinologists, ophthalmologists, retina specialists) to provide timely diagnosis and treatment for Spanish-speaking patients with DR/DME, especially those residing in rural areas, Discuss the efficacy and safety of anti-VEGF agents in a manner that acknowledges and overcomes patient barriers regarding their use, Implement communication strategies (eg, telehealth, patient education tools, translation services) to help reduce barriers to care and enhance healthcare delivery toward the goal of improving DR/DME outcomes in Spanish-speaking patients, especially those residing in rural areas.

John B. Buse, MD, PhD - Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets With GLP-1 RAs Apr 04, 2022

Go online to PeerView.com/AZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly! Upon completion of this CE activity, participants will be able to: Differentiate the therapeutic characteristics beyond glycemic control of GLP-1 RAs from other glucose-lowering agents, Construct individualized treatment regimens that uniquely target cardiometabolic and renal risk factors in patients with T2DM, Use shared decision-making with patients to discuss the ways GLP-1 RAs can be used safely and effectively to personalize treatment, improve adherence (eg, dosing frequency, route of administration), and reduce cardiometabolic risks.

Rohit Loomba, MD, MHSc - Test Your Knowledge of What’s Now and What’s Next: Modification of Metabolic Risk Factors to Improve Liver-Related and Cardiovascular‐Related Outcomes in NASH Mar 01, 2022

Go online to PeerView.com/FCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology provides practical guidance across the spectrum of care from screening and diagnosis to management of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Discuss the epidemiology and disease burden of NAFLD/NASH, Describe the relationship between NAFLD/NASH and cardiovascular disease, Assess current and emerging treatments for NASH in the context of mechanism of action (eg, ability to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression) and current clinical evidence (eg, impact on fibrosis and cardiovascular risk; safety)

Bradley S. Miller, MD, PhD - Advances in Pediatric Growth Hormone Therapy: Visualizing the Impact on Individualized Care Jan 20, 2022

Go online to PeerView.com/VUG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric growth hormone deficiency (pGHD) discusses the latest advances in treatment and patient-centered approaches to care. Upon completion of this activity, participants should be better able to: Identify appropriate pediatric candidates for growth hormone (GH) therapy based on approved indications, current recommendations, and relevant diagnostic test results, Evaluate evidence regarding the clinical characteristics (eg, efficacy, safety and tolerability, ease of administration, dosing frequency) of available and emerging GH therapies, Individualize pediatric GH therapy to include efforts that address patient needs and preferences, such as personalized dosing, therapeutic monitoring, and assistance with care transitions.

Domenica M. Rubino, MD & Donna H. Ryan, MD, FTOS -Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management Dec 10, 2021

Go online to PeerView.com/WBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Obesity is a complex chronic disease that can cause serious health complications. Current guidelines advocate for the use of multiple interventions to address the genetic, behavioral, and metabolic factors that contribute to insufficient weight loss or weight regain. Weight-loss pharmacotherapy is a recommended approach with distinct mechanisms of action that can affect different aspects of obesity pathophysiology. In this activity, based on a recent live web broadcast, leading experts examine the pathophysiology of obesity, focusing on metabolic adaptation and the role of GLP-1 in energy consumption and expenditure and review the latest evidence for GLP-1–based agents. The panel also discusses clinically relevant patient scenarios to offer practical guidance on identifying ideal candidates for weight-loss medications and integrating these medications into individualized treatment plans in order to optimize health outcomes and promote long-term weight loss. Upon completion of this CE activity, participants will be able to: Recognize the role of weight-loss pharmacotherapy used adjunct to other treatment approaches for addressing obesity pathophysiology, including metabolic adaptation, Assess available evidence on current and emerging GLP-1–based weight-loss pharmacotherapies, including long-term efficacy and safety data, Incorporate GLP-1–based weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.

Carl Regillo, MD - Clinical Colloquia in Retinal Disease: Updating Evidence-Based, Patient-Centered Care for Diabetic Retinopathy Nov 26, 2021

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented by noteworthy insights from a patient with DR/DME who will share her personal insights on diagnosis and treatment. This three-part activity is divided into multiple chapters for ease of navigation and access: Part 1. Great Expectations: What Are We Asking of Patients Undergoing DR/DME Treatment?, Part 2. Seeking a Higher Standard of Care: Advances in Therapy for DR/DME, Part 3. Patient Considerations and Newer Therapies: The Practical Side of Advances in Therapy for DR/DME. Upon completion of this activity, participants should be better able to: Describe challenges associated with current intravitreal treatment regimens for DR/DME from the patient perspective, Differentiate the benefits and limitations of current and emerging intravitreal agents for the treatment of DR/DME, Evaluate the evidence for current and emerging intravitreal agents to prevent vision-threatening outcomes in patients with DR/DME, Incorporate a personalized, patient-centered approach to the use of intravitreal therapies in patients with DR/DME.

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected